Knee cartilage injuries are among the most common and most undertreated musculoskeletal conditions. Whether the result of acute trauma, repetitive stress, or progressive degeneration, damaged cartilage limits mobility, causes chronic pain, and without appropriate intervention typically worsens over time. Yet surgery is not always the right answer: for many patients, nonsurgical treatment for knee cartilage injuries can provide meaningful and durable relief when the right approach is matched to the right patient.
This guide covers the full spectrum of evidence-based options from firstline conservative management through advanced regenerative therapies and explains how treatment selection depends on the type and stage of cartilage damage.
What Makes Knee Cartilage Injuries Different?
Articular cartilage is the smooth tissue covering the ends of bones inside the knee joint. Unlike bone or muscle, cartilage is avascular; it has no direct blood supply which severely limits its ability to repair itself naturally. Even relatively minor damage can progress if not addressed, leading to joint degeneration and pain that compounds over time.
Knee cartilage injuries span a spectrum: from small focal chondral defects localized areas of damage from trauma or overuse to diffuse cartilage loss associated with osteoarthritis (OA). This distinction matters because treatment options vary significantly by damage type and severity. A focal defect in an otherwise healthy knee responds differently to therapy than widespread early stage OA, and both differ from moderate to advanced articular degeneration.
Understanding where a patient falls on this spectrum is the essential first step. It determines whether the goal is symptom management, structural preservation, or active tissue repair.
FirstLine Care: Exercise, Physical Therapy, and Load Management
Before considering any injection or regenerative therapy, evidence-based guidelines consistently identify physical activity and structured exercise as the cornerstone of initial management.
The 2024 update to the EULAR (European League Against Rheumatism) recommendations for the nonpharmacological management of knee osteoarthritis classifies exercise as a core firstline treatment supported by Level 1a1b evidence the highest available evidence tier based on 15 systematic reviews and 11 additional randomized controlled trials (EULAR, 2024001298/).
A concern frequently raised by patients is whether exercise may accelerate cartilage damage. A 2023 systematic review and network metaanalysis found that physical activity has a positive or neutral effect on structural cartilage integrity in 13 out of 14 comparisons, with no evidence that exercise increases the risk of radiographic OA progression in 6 out of 7 studies reviewed (PMC, 2023). Despite this robust evidence base, fewer than 40% of knee OA patients currently receive a structured exercise intervention, one of the most significant gaps in standard care.
Practical components of firstline management include:
- Supervised physical therapy targeting quadriceps and hip abductor strength
- Low impact aerobic activity (aquatic therapy, cycling)
- Activity modification to reduce provocative loading
- Weight management where applicable
These measures form the biological foundation on which injection and regenerative therapies build. Skipping this step reduces the effectiveness of any subsequent treatment.
IntraArticular Injections: From Symptom Relief to Tissue Repair
When conservative management is insufficient, intraarticular injections represent the next tier of treatment. Not all injections are equivalent; they differ substantially in mechanism, duration of effect, and long-term tissue impact.
Corticosteroid Injections
Corticosteroid injections are widely used for acute flare management and short-term pain control. A 2024 systematic review and metaanalysis found that intraarticular corticosteroids provide clinically perceivable benefit compared to placebo but only at short-term followup, with clinical relevance declining significantly beyond six weeks (KSSA, 2024). The same review noted that corticosteroid injections were associated with greater cartilage volume loss compared to saline at two-year follow-up. This evidence limits their appropriate role to acute symptom control rather than ongoing cartilage management.
Hyaluronic Acid (HA) Therapy
Hyaluronic acid injections work by supplementing the viscosity and lubrication of synovial fluid, reducing friction and supporting joint function. A 2025 systematic umbrella review found that intraarticular HA demonstrates moderate efficacy for pain relief and functional improvement, with effectiveness most pronounced in early to moderate OA stages and dependent on product formulation (molecular weight and crosslinking) (PMC, 2025). Evidence also suggests that combining HA with PRP produces synergistic benefits that outperform either treatment alone.
PlateletRich Plasma (PRP) Therapy
PRP therapy involves concentrating platelets and bioactive growth factors from a patient’s own blood and injecting the preparation directly into the knee joint. The growth factors including PDGF, TGFβ, and VEGF stimulate tissue repair mechanisms and modulate local inflammation.
The evidence base for PRP in knee conditions is now substantial. A 2025 metaanalysis of 15 doubleblind randomized controlled trials involving 1,632 patients found that PRP produced significantly lower WOMAC pain scores compared to hyaluronic acid at 12 months, with improvements exceeding the minimal clinically important difference (MCID). Leukocytepoor PRP demonstrated superior pain relief compared to both corticosteroids and HA (PMC, 2025). PRP represents a meaningful step toward tissuelevel intervention rather than purely symptomatic relief.
Regenerative Medicine for Knee Cartilage
For patients with more significant cartilage loss or persistent symptoms after conventional care, regenerative medicine for knee cartilage offers biologically active approaches that go beyond lubrication or grow factor stimulation.
Mesenchymal Stem Cell (MSC) Therapy
Stem cell therapy using mesenchymal stromal cells (MSCs) sourced from bone marrow or adipose tissue represents the most biologically sophisticated tier of cartilage treatment. MSCs support repair through paracrine signaling: releasing antiinflammatory cytokines and growth factors that promote local tissue healing and may support cartilage matrix restoration.
A 2023 systematic review of 15 RCTs found that 11 out of 15 showed net positive effects on pain compared to control conditions, 12 out of 15 showed functional improvement versus baseline, and cartilage protection or repair was demonstrated in 18 out of 21 clinical studies. Highdose adiposederived MSC injections were associated with hyalinelike cartilage regeneration on MRI in some studies (Nature, 2023). Most MSC applications remain investigational or offlabel, making thorough pretreatment evaluation essential.
Exosome Therapy
Exosomes are cell-derived nanoparticles that carry microRNAs and signaling proteins between cells. MSCderived exosomes have emerged as a cellfree alternative to whole stem cell injections, with preclinical evidence suggesting they promote chondrocyte proliferation, inhibit cartilage cell death, and reduce proinflammatory cytokines in the joint environment. A 2024 review synthesizing 28 preclinical studies found consistent therapeutic advantages, with twiceweekly injection protocols outperforming onceweekly dosing and best outcomes in early-to-moderate OA (Kellgren Lawrence grade 12) (Frontiers, 2024). Human clinical trials are ongoing; this remains an emerging but promising area.
Peptide Therapy
Peptide therapy is an evolving component of regenerative orthopedic care. Clinical evidence for knee-specific applications remains limited; peptide strategies are currently integrated into personalized functional health plans on an investigational basis.
Is Nonsurgical Treatment Right for You?
Most patients with knee cartilage injuries are appropriate candidates for a nonsurgical approach, particularly those who:
- Have early-to-moderate cartilage damage confirmed on imaging
- Have persistent symptoms despite conservative care (exercise, PT, weight management)
- Wish to avoid or delay surgery
- Have no active infection, malignancy, or severe structural instability requiring surgical decompression
Nonsurgical approaches are generally not appropriate for patients with advanced bone on bone changes, progressive neurological symptoms, or conditions where decompression or structural reconstruction cannot be deferred.
A comprehensive evaluation before any injection is essential including comprehensive blood work, inflammatory markers, hormonal assessment, and imaging review. This root cause assessment helps identify systemic contributors to joint deterioration such as chronic inflammation, metabolic dysfunction, or hormonal imbalance that would limit the effectiveness of any injection if left unaddressed.
Frequently Asked Questions
What is the best nonsurgical treatment for knee cartilage injuries?
There is no single best option; the most appropriate treatment depends on the type and stage of cartilage damage. For mild early stage injury, structured exercise combined with PRP or HA therapy is generally the evidence supported starting point. For moderate damage or persistent symptoms, PRP with or without MSC therapy may be considered. For focal defects, cellbased regenerative approaches or specialist evaluation are typically indicated.
Can knee cartilage repair itself without surgery?
Articular cartilage has very limited natural repair capacity due to its lack of blood supply. While minor surface damage may stabilize with appropriate load management, significant chondral defects or degenerative changes do not heal spontaneously. Regenerative therapies aim to create a biological environment that supports partial repair and tissue preservation, a meaningful but distinct goal from complete regeneration.
Is PRP effective for knee cartilage injuries?
Evidence suggests PRP may be effective for degenerative knee cartilage conditions. A 2025 metaanalysis of 15 doubleblind RCTs involving 1,632 patients found PRP superior to hyaluronic acid and corticosteroids for pain reduction at 12 months, with improvements exceeding the MCID. Results vary by preparation protocol, platelet concentration, and patient selection.
How long does nonsurgical treatment for knee cartilage injuries take to work?
Timelines vary by modality. Exercise and physical therapy typically produce measurable improvements in pain and function within 6–12 weeks. PRP therapy generally shows initial response within 4–8 weeks, with full effect at 3–6 months. MSCbased therapies may require up to 12 months for full tissue response. Individual results depend on damage severity, age, and overall metabolic health.
What is regenerative medicine for knee cartilage?
Regenerative medicine for knee cartilage refers to biologically active treatments including PRP, mesenchymal stem cell injections, exosome therapy, and peptide-based approaches that aim to support cartilage repair and preservation at the tissue level, rather than masking symptoms. These therapies leverage the body’s own biological signaling mechanisms to promote healing in an environment where natural repair is insufficient.
Are corticosteroid injections bad for knee cartilage?
Corticosteroids are appropriate for short-term acute flare management, but evidence suggests they are not appropriate as an ongoing treatment strategy. A 2024 systematic review and metaanalysis found that the clinical benefit of corticosteroid injections is only meaningful in the first six weeks, and that repeated injections were associated with greater cartilage volume loss compared to saline at two-year follow-up. This does not make them universally harmful, but it reinforces that they should be used sparingly and in the context of a broader care plan.
Key Takeaways
- The full treatment spectrum ranges from exercise and PT (firstline) through intraarticular injections to advanced regenerative therapies and selection should match the specific type and stage of damage
- EULAR 2024 guidelines classify exercise as core firstline care (Level 1a1b); fewer than 40% of patients currently receive structured exercise intervention
- Corticosteroid injections provide short-term benefit only (<6 weeks clinical relevance) and are associated with cartilage volume loss at 2 years a key reason to consider regenerative alternatives
- PRP is supported by a 2025 metaanalysis of 15 RCTs (n=1,632) showing superiority over HA and steroids at 12 months; HA+PRP combination shows synergistic benefits
- Advanced regenerative approaches MSC therapy, exosome therapy, and peptide-based adjuncts represent an evolving tier for moderate-to-advanced damage; most remain investigational and require personalized evaluation
- A thorough root cause evaluation including bloodwork, inflammatory markers, and imaging should precede any injection recommendation
Ready to Explore Your Options?
If you are exploring nonsurgical treatment for knee cartilage injuries, schedule a consultation with Ways2Well and get a personalized evaluation that includes imaging review, functional assessment, and a regenerative care plan tailored to your specific injury.
References
1. “EULAR recommendations for the nonpharmacological core management of hip and knee osteoarthritis: 2023 update.” Annals of the Rheumatic Diseases, 2024. URL: https://ard.eular.org/article/S00034967(24)001298/fulltext001298/)
2. “Exercise Therapy for Knee Osteoarthritis: A Systematic Review and Network Metaanalysis.” PMC, 2023. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10280533/
3. “Intraarticular corticosteroid injections provide a clinically relevant benefit compared to placebo only at short-term followup in patients with knee osteoarthritis: A systematic review and metaanalysis.” Knee Surgery, Sports Traumatology, Arthroscopy, 2024. URL: https://esskajournals.onlinelibrary.wiley.com/doi/10.1002/ksa.12057
4. “IntraArticular Hyaluronic Acid for Knee Osteoarthritis: A Systematic Umbrella Review.” PMC / MDPI, 2025. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC11856182/
5. “PRP Injections for the Treatment of Knee Osteoarthritis: The Improvement Is Clinically Significant and Influenced by Platelet Concentration: A Metaanalysis of Randomized Controlled Trials.” PMC, 2025. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC11874499/
6. “Cultureexpanded mesenchymal stromal cell therapy: does it work in knee osteoarthritis? A pathway to clinical success.” Nature / Cellular & Molecular Immunology, 2023. URL: https://www.nature.com/articles/s41423023010201
7. “Mesenchymal stem cellderived exosomes as a promising cellfree therapy for knee osteoarthritis.” Frontiers in Bioengineering and Biotechnology, 2024. URL: https://www.frontiersin.org/journals/bioengineeringandbiotechnology/articles/10.3389/fbioe.2024.1309946/
8. “The effect of dextrose prolotherapy on patients diagnosed with knee osteoarthritis: A comprehensive systematic review and metaanalysis of interventional studies.” Wiley / Health Science Reports, 2024. URL: https://onlinelibrary.wiley.com/doi/10.1002/hsr2.2145
9. “Treatment of knee cartilage lesions in 2024: From hyaluronic acid to regenerative medicine.” PMC, 2024. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10985633/
10. “Emerging Use of BPC157 in Orthopaedic Sports Medicine: A Systematic Review.” PMC, 2025. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/
Author: Ways2Well Editorial Team
Reviewed by: Scientific Advisory Board member